![Cell signaling / CD135 / Acute myeloid leukemia / Organic chemistry / Quizartinib / Tyrosine kinase / Astellas Pharma / Leukemia / Lestaurtinib / Oncology / Acute leukemia / Myeloid leukemia Cell signaling / CD135 / Acute myeloid leukemia / Organic chemistry / Quizartinib / Tyrosine kinase / Astellas Pharma / Leukemia / Lestaurtinib / Oncology / Acute leukemia / Myeloid leukemia](https://www.pdfsearch.io/img/80043791e6c796767f66a13415afd90d.jpg)
| Document Date: 2011-08-15 11:58:25 Open Document File Size: 86,92 KBShare Result on Facebook
City Tokyo / San Diego / / Company BIOSCIENCES AND ASTELLAS ENTER STRATEGIC PARTNERSHIP / Cephalon / Ambit Biosciences Ambit Biosciences / Ambit Biosciences Corporation / Astellas Pharma Inc. / / Continent Europe / / Country Japan / United States / / Currency USD / / Event Business Partnership / FDA Phase / / IndustryTerm oncology products / pharmaceuticals / treatment of cancer / pharmaceutical / privately-held biopharmaceutical / kinase profiling technology / / MedicalCondition cancer / solid tumor cancers / metabolic diseases / blood cancers / infectious diseases / inflammatory disease / blood cancer / acute myeloid leukemia / / MedicalTreatment combination chemotherapy / chemotherapy / / Organization American Cancer Society / / Person Masafumi Nogimori / Scott Salka / / Position Chief Executive Officer / president and chief executive officer / global category leader / / Product AC220 / AC480 / FLT3 / / ProvinceOrState Aurora / California / / Technology neuroscience / drug discovery / chemotherapy / kinase profiling technology / / URL http /
SocialTag |